0001144204-18-064217.txt : 20181212 0001144204-18-064217.hdr.sgml : 20181212 20181212131538 ACCESSION NUMBER: 0001144204-18-064217 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181203 FILED AS OF DATE: 20181212 DATE AS OF CHANGE: 20181212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paley Jeffrey CENTRAL INDEX KEY: 0001595327 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38114 FILM NUMBER: 181230563 MAIL ADDRESS: STREET 1: C/O RETROPHIN INC., 777 THIRD AVENUE STREET 2: 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER NAME: FORMER CONFORMED NAME: Paley Jeffery DATE OF NAME CHANGE: 20131224 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVENUE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001644963 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474113275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 4 1 tv508813_form4.xml FORM 4 X0306 4 2018-12-03 0 0001644963 AVENUE THERAPEUTICS, INC. ATXI 0001595327 Paley Jeffrey C/O AVENUE THERAPEUTICS, INC. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 1 0 0 0 Common Stock 2018-12-03 4 P 0 10000 5.4754 A 74663 D Common Stock 2018-12-10 4 P 0 5000 4.76 A 79663 D Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on December 3, 2018 was $5.4734 to $5.4774. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Includes 64,663 shares of restricted stock. /s/ Lucy Lu, M.D., Attorney-in-Fact 2018-12-12